Tim Fugmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tim Fugmann has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Dario Neri
Philochem AG, Otelfingen, Switzerland
38 shared publications Marco Stringhini
18 shared publications- Philipp Probst
Araris Biotech AG, Au ZH, Switzerland
18 shared publications Theo Sturm
18 shared publicationsBarbara Ziffels
17 shared publications- Christoph Roesli
Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
9 shared publications
Latest Publications
- Open Access
- 2 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (1) , eaeb0821
HLA-Shuttle: A system for enhancing antigen presentation in immunologically cold tumors
Epitopic peptides presented by class-I human leukocyte antigen (HLA-I) proteins provide the basis of immune surveillance by T cells. Conversely, reduced surface HLA-I expression is a hallmark of immune evasion by latent viral infections and cancer, which confounds the identification of peptide antigens and neoantigens. Here, we outline a system (HLA-Shuttle) for in vitro manipulation of cells with engineered components of the HLA-I processing machinery to confer a continuum of chaperoning activity throughout their trafficking pathway. HLA-Shuttle restores antigen presentation in immunologically cold neuroblastoma cells, enabling identification of multiple tumor-associated antigens with therapeutic potential. Cellular trafficking assays and single-particle tracking reveal a global stabilization of HLA-I molecules, extension of their cell-surface lifetime and microdomain formation. HLA-Shuttle can be used across a range of aberrant cellular states where low antigen expression remains a bottleneck for the identification of endogenous peptide antigens.
- 2 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (1) , eaeb0821
Open AccessHLA-Shuttle: A system for enhancing antigen presentation in immunologically cold tumors
Epitopic peptides presented by class-I human leukocyte antigen (HLA-I) proteins provide the basis of immune surveillance by T cells. Conversely, reduced surface HLA-I expression is a hallmark of immune evasion by latent viral infections and cancer, which confounds the identification of peptide antigens and neoantigens. Here, we outline a system (HLA-Shuttle) for in vitro manipulation of cells with engineered components of the HLA-I processing machinery to confer a continuum of chaperoning activity throughout their trafficking pathway. HLA-Shuttle restores antigen presentation in immunologically cold neuroblastoma cells, enabling identification of multiple tumor-associated antigens with therapeutic potential. Cellular trafficking assays and single-particle tracking reveal a global stabilization of HLA-I molecules, extension of their cell-surface lifetime and microdomain formation. HLA-Shuttle can be used across a range of aberrant cellular states where low antigen expression remains a bottleneck for the identification of endogenous peptide antigens.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
Antibody–cytokine fusion proteins can have the potential to increase the density and activity of subsets of leukocytes within the tumor mass. Here, we describe the design, production, and characterization of four novel antibody–cytokine fusion proteins directed against human carbonic anhydrase IX, a highly validated marker of hypoxia that is overexpressed in clear cell renal cell carcinoma and other malignancies. As immunomodulatory payloads we used TNF, IL2, IFNα2 (corresponding to products that are in clinical use), and IL12 (as this cytokine potently activates T cells and NK cells). Therapy experiments were performed in BALB/c mice, bearing CT26 tumors transfected with human carbonic anhydrase IX, in order to assess the performance of the fusion proteins in an immunocompetent setting. The biopharmaceuticals featuring TNF, IL2, or IL12 as payloads cured all mice in their therapy groups, whereas only a subset of mice was cured by the antibody-based delivery of IFNα2. Although the antibody fusion with TNF mediated a rapid hemorrhagic necrosis of the tumor mass, a slower regression of the neoplastic lesions (which continued after the last injection) was observed with the other fusion proteins, and treated mice acquired protective anticancer immunity. A high proportion of tumor-infiltrating CD8+ T cells was specific to the retroviral antigen AH1; however, the LGPGREYRAL peptide derived from human carbonic anhydrase IX was also present on tumor cells. The results described herein provide a rationale for the clinical use of fully human antibody–cytokine fusions specific to carbonic anhydrase IX.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
Antibody–cytokine fusion proteins can have the potential to increase the density and activity of subsets of leukocytes within the tumor mass. Here, we describe the design, production, and characterization of four novel antibody–cytokine fusion proteins directed against human carbonic anhydrase IX, a highly validated marker of hypoxia that is overexpressed in clear cell renal cell carcinoma and other malignancies. As immunomodulatory payloads we used TNF, IL2, IFNα2 (corresponding to products that are in clinical use), and IL12 (as this cytokine potently activates T cells and NK cells). Therapy experiments were performed in BALB/c mice, bearing CT26 tumors transfected with human carbonic anhydrase IX, in order to assess the performance of the fusion proteins in an immunocompetent setting. The biopharmaceuticals featuring TNF, IL2, or IL12 as payloads cured all mice in their therapy groups, whereas only a subset of mice was cured by the antibody-based delivery of IFNα2. Although the antibody fusion with TNF mediated a rapid hemorrhagic necrosis of the tumor mass, a slower regression of the neoplastic lesions (which continued after the last injection) was observed with the other fusion proteins, and treated mice acquired protective anticancer immunity. A high proportion of tumor-infiltrating CD8+ T cells was specific to the retroviral antigen AH1; however, the LGPGREYRAL peptide derived from human carbonic anhydrase IX was also present on tumor cells. The results described herein provide a rationale for the clinical use of fully human antibody–cytokine fusions specific to carbonic anhydrase IX.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 - In vitro characterization of and therapy study with XE-mIL12. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
A) cloning scheme of XE-mIL12. b) expected protein structure, yield of TGE in CHO-S cells and expected molecular weight. c) SDS-PAGE analysis (kDa: marker in kDa, nr: non-reduced, r: reduced). d) Size exclusion profile and standard proteins indicated by black arrows (1: IgG, 145 kDa, 2: BSA, 67 kDa, 3: Diabody, 25 kDa). e) MS profile. f) BALB/c mice bearing CT26 tumors transfected with human CAIX received three injections every 72 hours of either PBS as control or 12 µg of XE-mIL12. Statistical significance towards PBS control group is shown on day 19, *p<0.05. g) Body weight change during the treatment phase.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 - In vitro characterization of and therapy study with XE-mIL12. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
A) cloning scheme of XE-mIL12. b) expected protein structure, yield of TGE in CHO-S cells and expected molecular weight. c) SDS-PAGE analysis (kDa: marker in kDa, nr: non-reduced, r: reduced). d) Size exclusion profile and standard proteins indicated by black arrows (1: IgG, 145 kDa, 2: BSA, 67 kDa, 3: Diabody, 25 kDa). e) MS profile. f) BALB/c mice bearing CT26 tumors transfected with human CAIX received three injections every 72 hours of either PBS as control or 12 µg of XE-mIL12. Statistical significance towards PBS control group is shown on day 19, *p<0.05. g) Body weight change during the treatment phase.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 - Immunopeptidome prediction of human CAIX. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
The prediction revealed more than 350 9-12mers potentially binding to the murine MHC class I alleles H-2Kd, H-2Dd and H-2Ld, leading to further immunopeptidome analysis of CT26 cells stably transfected with human CAIX.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 - Immunopeptidome prediction of human CAIX. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
The prediction revealed more than 350 9-12mers potentially binding to the murine MHC class I alleles H-2Kd, H-2Dd and H-2Ld, leading to further immunopeptidome analysis of CT26 cells stably transfected with human CAIX.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 - In vitro characterization of F8-mIFNa2 and therapy study with either F8-mIFNa2, Doxorubicin or the combination in BALB/c mice bearing WEHI-164 sarcoma. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
A) cloning scheme. b) expected protein structure, yield of TGE in CHO-S cells and expected molecular weight. c) SDS-PAGE analysis (kDa: marker in kDa, nr: non-reduced, r: reduced). d) Size exclusion profile and standard proteins indicated by black arrows (1: IgG, 145 kDa, 2: BSA, 67 kDa, 3: Diabody, 25 kDa). e) MS profile. f) BIAcore profile using a human EDA coated CM5 sensor chip. g) Activity assay for the respective payload. h) WEHI-164 sarcoma bearing BALB/c mice received either PBS as control (three injections) or 5 mg/kg Doxorubicin (one injection) or 150 µg of F8-mIFNa2 (three injections) or the combination of Doxorubicin and F8-mIFNa2. Statistical significance towards PBS control group is shown on day 14, *p<0.05, **p<0.005, ***p<0.0005. i) Body weight change during the treatment phase.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 - In vitro characterization of F8-mIFNa2 and therapy study with either F8-mIFNa2, Doxorubicin or the combination in BALB/c mice bearing WEHI-164 sarcoma. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
A) cloning scheme. b) expected protein structure, yield of TGE in CHO-S cells and expected molecular weight. c) SDS-PAGE analysis (kDa: marker in kDa, nr: non-reduced, r: reduced). d) Size exclusion profile and standard proteins indicated by black arrows (1: IgG, 145 kDa, 2: BSA, 67 kDa, 3: Diabody, 25 kDa). e) MS profile. f) BIAcore profile using a human EDA coated CM5 sensor chip. g) Activity assay for the respective payload. h) WEHI-164 sarcoma bearing BALB/c mice received either PBS as control (three injections) or 5 mg/kg Doxorubicin (one injection) or 150 µg of F8-mIFNa2 (three injections) or the combination of Doxorubicin and F8-mIFNa2. Statistical significance towards PBS control group is shown on day 14, *p<0.05, **p<0.005, ***p<0.0005. i) Body weight change during the treatment phase.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 - DNA and amino acid sequences of XE-mTNF, XE-hIL2, XE-mIFNa2 and XE-mIL12. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
Colour code identification of the respective DNA and amino acid sequences is used as displayed in the respective headline.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 - DNA and amino acid sequences of XE-mTNF, XE-hIL2, XE-mIFNa2 and XE-mIL12. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
Colour code identification of the respective DNA and amino acid sequences is used as displayed in the respective headline.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 - Activity of targeted (XE) and non-targeted (KSF) mTNF, hIL2 and mIFNa2 in BALB/c mice bearing CT26 tumors transfected with human CAIX. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
A, b, c) Tumor bearing mice received three injections of either 2 µg XE-mTNF or 2 µg KSF-mTNF(a), 30 µg XE-hIL2 or 30 µg KSF-hIL2(b) or 80 µg XE-mIFNa2 or 80 µg KSF-mIFNa2(c)or saline (PBS) as control, starting when tumors reached a size of 90 mm3. Data are represented as mean (n=3) + SEM. Statistical significance is shown on day 15, n.s.=non-significant, *p<0.05, ***p<0.0005, ****p<0.0001. d, e, f) Body weight change during the treatment phase of the therapies depicted in a, b, c. g) Pictures of representative tumor growth taken before (day 7) and after treatment (day 12).
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 - Activity of targeted (XE) and non-targeted (KSF) mTNF, hIL2 and mIFNa2 in BALB/c mice bearing CT26 tumors transfected with human CAIX. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
A, b, c) Tumor bearing mice received three injections of either 2 µg XE-mTNF or 2 µg KSF-mTNF(a), 30 µg XE-hIL2 or 30 µg KSF-hIL2(b) or 80 µg XE-mIFNa2 or 80 µg KSF-mIFNa2(c)or saline (PBS) as control, starting when tumors reached a size of 90 mm3. Data are represented as mean (n=3) + SEM. Statistical significance is shown on day 15, n.s.=non-significant, *p<0.05, ***p<0.0005, ****p<0.0001. d, e, f) Body weight change during the treatment phase of the therapies depicted in a, b, c. g) Pictures of representative tumor growth taken before (day 7) and after treatment (day 12).
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 - In vitro characterization of F8-mIFNa2 and therapy study with either F8-mIFNa2, Doxorubicin or the combination in BALB/c mice bearing WEHI-164 sarcoma. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
A) cloning scheme. b) expected protein structure, yield of TGE in CHO-S cells and expected molecular weight. c) SDS-PAGE analysis (kDa: marker in kDa, nr: non-reduced, r: reduced). d) Size exclusion profile and standard proteins indicated by black arrows (1: IgG, 145 kDa, 2: BSA, 67 kDa, 3: Diabody, 25 kDa). e) MS profile. f) BIAcore profile using a human EDA coated CM5 sensor chip. g) Activity assay for the respective payload. h) WEHI-164 sarcoma bearing BALB/c mice received either PBS as control (three injections) or 5 mg/kg Doxorubicin (one injection) or 150 µg of F8-mIFNa2 (three injections) or the combination of Doxorubicin and F8-mIFNa2. Statistical significance towards PBS control group is shown on day 14, *p<0.05, **p<0.005, ***p<0.0005. i) Body weight change during the treatment phase.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 - In vitro characterization of F8-mIFNa2 and therapy study with either F8-mIFNa2, Doxorubicin or the combination in BALB/c mice bearing WEHI-164 sarcoma. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
A) cloning scheme. b) expected protein structure, yield of TGE in CHO-S cells and expected molecular weight. c) SDS-PAGE analysis (kDa: marker in kDa, nr: non-reduced, r: reduced). d) Size exclusion profile and standard proteins indicated by black arrows (1: IgG, 145 kDa, 2: BSA, 67 kDa, 3: Diabody, 25 kDa). e) MS profile. f) BIAcore profile using a human EDA coated CM5 sensor chip. g) Activity assay for the respective payload. h) WEHI-164 sarcoma bearing BALB/c mice received either PBS as control (three injections) or 5 mg/kg Doxorubicin (one injection) or 150 µg of F8-mIFNa2 (three injections) or the combination of Doxorubicin and F8-mIFNa2. Statistical significance towards PBS control group is shown on day 14, *p<0.05, **p<0.005, ***p<0.0005. i) Body weight change during the treatment phase.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 - Activity of targeted (XE) and non-targeted (KSF) mTNF, hIL2 and mIFNa2 in BALB/c mice bearing CT26 tumors transfected with human CAIX. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
A, b, c) Tumor bearing mice received three injections of either 2 µg XE-mTNF or 2 µg KSF-mTNF(a), 30 µg XE-hIL2 or 30 µg KSF-hIL2(b) or 80 µg XE-mIFNa2 or 80 µg KSF-mIFNa2(c)or saline (PBS) as control, starting when tumors reached a size of 90 mm3. Data are represented as mean (n=3) + SEM. Statistical significance is shown on day 15, n.s.=non-significant, *p<0.05, ***p<0.0005, ****p<0.0001. d, e, f) Body weight change during the treatment phase of the therapies depicted in a, b, c. g) Pictures of representative tumor growth taken before (day 7) and after treatment (day 12).
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 - Activity of targeted (XE) and non-targeted (KSF) mTNF, hIL2 and mIFNa2 in BALB/c mice bearing CT26 tumors transfected with human CAIX. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
A, b, c) Tumor bearing mice received three injections of either 2 µg XE-mTNF or 2 µg KSF-mTNF(a), 30 µg XE-hIL2 or 30 µg KSF-hIL2(b) or 80 µg XE-mIFNa2 or 80 µg KSF-mIFNa2(c)or saline (PBS) as control, starting when tumors reached a size of 90 mm3. Data are represented as mean (n=3) + SEM. Statistical significance is shown on day 15, n.s.=non-significant, *p<0.05, ***p<0.0005, ****p<0.0001. d, e, f) Body weight change during the treatment phase of the therapies depicted in a, b, c. g) Pictures of representative tumor growth taken before (day 7) and after treatment (day 12).